The fight against Antimicrobial Resistance (AMR) is challenging due to financial, ethical, and legislative issues. Combating infectious disease can prove to be a risky financial investment but much less in comparison to the global impact if solutions are not researched.
Alfonso Chang is the Managing Director of Relativity Healthcare Partners; he shares insight into the challenges and how to overcome them:
- Investor Hesitancy
- Higher clinical and ethical implications
- Preference of existing therapies over new ones
- Unintended consequences from lawmakers due to drafted legislative language
Check out the resources below for more information:
- Alfonso’s LinkedIn
- Our host: John Stanford’s LinkedIn
To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.
